Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Feb 24;64(9):1321–1325. doi: 10.1136/ard.2004.031856

Real world experience with antiphospholipid antibody tests: how stable are results over time?

D Erkan 1, W Derksen 1, V Kaplan 1, L Sammaritano 1, S Pierangeli 1, R Roubey 1, M Lockshin 1
PMCID: PMC1755632  PMID: 15731290

Abstract

Objective: To determine the stability and the degree of variation of antiphospholipid antibody (aPL) results over time in a large cohort of well evaluated aPL positive patients; and to analyse factors contributing to aPL variation and the validity of aPL in a real world setting in which aPL tests are done in multiple laboratories.

Methods: The clinical characteristics, drug treatment, and 1652 data points for lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-ß2 glycoprotein I antibodies (anti-ß2GPI) were examined in 204 aPL positive patients; 81 of these met the Sapporo criteria for antiphospholipid syndrome (APS) and 123 were asymptomatic bearers of aPL.

Results: 87% of initially positive LA results, 88% of initially negative to low positive aCL results, 75% of initially moderate to high positive aCL results, 96% of initially negative to low positive anti-ß2GPI results, and 76% of initially moderate to high positive anti-ß2GPI results subsequently remained in the same range regardless of the laboratory performing the test. Aspirin, warfarin, and hydroxychloroquine use did not differ among patients whose aCL titres significantly decreased or increased or remained stable. On same day specimens, the consistency of aCL results among suppliers ranged from 64% to 88% and the correlation ranged from 0.5 to 0.8. Agreement was moderate for aCL IgG and aCL IgM; however, for aCL IgA agreement was marginal.

Conclusions: aPL results remained stable for at least three quarters of subsequent tests, regardless of the laboratory performing the test; the small amount of variation that occurred did not appear to be caused by aspirin, warfarin, or hydroxychloroquine use.

Full Text

The Full Text of this article is available as a PDF (78.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Audrain Marie A. P., Colonna Françoise, Morio Florent, Hamidou Mohamed A., Muller Jean-Yves. Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1. Rheumatology (Oxford) 2003 Oct 29;43(2):181–185. doi: 10.1093/rheumatology/keh029. [DOI] [PubMed] [Google Scholar]
  2. Brandt J. T., Triplett D. A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995 Oct;74(4):1185–1190. [PubMed] [Google Scholar]
  3. Bruce I. N., Clark-Soloninka C. A., Spitzer K. A., Gladman D. D., Urowitz M. B., Laskin C. A. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol. 2000 Dec;27(12):2833–2837. [PubMed] [Google Scholar]
  4. Finazzi G. The Italian Registry of Antiphospholipid Antibodies. Haematologica. 1997 Jan-Feb;82(1):101–105. [PubMed] [Google Scholar]
  5. Galli Monica. Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' risk? Thromb Res. 2004;114(5-6):597–601. doi: 10.1016/j.thromres.2004.08.009. [DOI] [PubMed] [Google Scholar]
  6. Galli Monica, Luciani Davide, Bertolini Guido, Barbui Tiziano. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2002 Oct 3;101(5):1827–1832. doi: 10.1182/blood-2002-02-0441. [DOI] [PubMed] [Google Scholar]
  7. Ginsburg K. S., Liang M. H., Newcomer L., Goldhaber S. Z., Schur P. H., Hennekens C. H., Stampfer M. J. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992 Dec 15;117(12):997–1002. doi: 10.7326/0003-4819-117-12-997. [DOI] [PubMed] [Google Scholar]
  8. Harris E. N. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol. 1990 Oct;94(4):476–484. doi: 10.1093/ajcp/94.4.476. [DOI] [PubMed] [Google Scholar]
  9. Kalunian K. C., Peter J. B., Middlekauff H. R., Sayre J., Ando D. G., Mangotich M., Hahn B. H. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med. 1988 Nov;85(5):602–608. doi: 10.1016/s0002-9343(88)80229-8. [DOI] [PubMed] [Google Scholar]
  10. Lee Eun Young, Lee Chang-Keun, Lee Tae Hoon, Chung Son Mi, Kim Seong Ho, Cho You Sook, Yoo Bin, Moon Hee-Bom. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res. 2003;111(1-2):29–32. doi: 10.1016/j.thromres.2003.08.023. [DOI] [PubMed] [Google Scholar]
  11. Levine S. R., Salowich-Palm L., Sawaya K. L., Perry M., Spencer H. J., Winkler H. J., Alam Z., Carey J. L. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke. 1997 Sep;28(9):1660–1665. doi: 10.1161/01.str.28.9.1660. [DOI] [PubMed] [Google Scholar]
  12. Lockshin M. D., Druzin M. L., Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol. 1989 Feb;160(2):439–443. doi: 10.1016/0002-9378(89)90468-7. [DOI] [PubMed] [Google Scholar]
  13. Nojima J., Suehisa E., Akita N., Toku M., Fushimi R., Tada H., Kuratsune H., Machii T., Kitani T., Amino N. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol. 1997 Mar;96(3):447–450. doi: 10.1046/j.1365-2141.1997.d01-2055.x. [DOI] [PubMed] [Google Scholar]
  14. Out H. J., van Vliet M., de Groot P. G., Derksen R. H. Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992 Mar;51(3):353–357. doi: 10.1136/ard.51.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Reber Guido, Schousboe Inger, Tincani Angela, Sanmarco Marielle, Kveder Tanja, de Moerloose Philippe, Boffa Marie-Claire, Arvieux Josiane. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost. 2002 Jul;88(1):66–73. [PubMed] [Google Scholar]
  16. Vila P., Hernández M. C., López-Fernández M. F., Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994 Aug;72(2):209–213. [PubMed] [Google Scholar]
  17. Wilson W. A., Gharavi A. E., Koike T., Lockshin M. D., Branch D. W., Piette J. C., Brey R., Derksen R., Harris E. N., Hughes G. R. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999 Jul;42(7):1309–1311. doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  18. Wong Richard C. W., Australasian aCL Working Party Consensus guidelines for anticardiolipin antibody testing. Thromb Res. 2004;114(5-6):559–571. doi: 10.1016/j.thromres.2004.06.002. [DOI] [PubMed] [Google Scholar]
  19. Wong Richard, Wilson Robert, Pollock Wendy, Steele Richard, Gillis David. Anti-cardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology. 2004 Apr;36(2):174–181. doi: 10.1080/00313020410001672046. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES